著名免疫学家Alberto Mantovani教授参访复星医药成员企业复宏汉霖上海创新中心
转自：复星医药
近日，复宏汉霖科学顾问委员会（ScientificAdvisoryBoard,SAB）成员、意大利Humanitas临床和研究中心的科学总监和名誉教授AlbertoMantovani应邀参访复宏汉霖上海创新中心，就前沿技术及全球创新趋势进行分享交流。
Mantovani教授是免疫学和炎症领域的知名专家，具有深厚的研究经验，在炎症与肿瘤关系方面取得一系列开创性成果，是该领域的领军人物。此次参访，Mantovani教授以《从癌症到COVID-19的先天免疫与炎症》为题，结合复宏汉霖的早期研发方向，有针对性地分享了巨噬细胞、白介素-1（IL-1）家族和IL-1受体家族等免疫、炎症重要成分/介质在疾病中发挥的作用，揭示了先天免疫、炎症、肿瘤和COVID-19等疾病发病机制之间的错综联系和多类疾病间的系统性治疗策略，并与复宏汉霖的研发人员展开了深入讨论，为新型抗肿瘤药物和免疫炎症药物的研发提供了思路。
复宏汉霖上海创新中心总经理单永强博士代表公司对Mantovani教授分享的专业知识和见解表示感谢。Mantovani教授和其他国际领军专家组成的科学顾问委员会在指导公司的研发方向和推动技术创新等方面发挥着重要的作用。此次Mantovani教授的到访为复宏汉霖后续的研发工作指点了创新方向，开拓了研发团队的国际视野，知识和思想的碰撞将为复宏汉霖进一步开发新型疗法提供支持，助力解决更多未满足的临床需求。
未来，复宏汉霖将继续推动与更多全球顶尖科学家的交流与合作，促进科技成果转化，加速创新疗法的开发，惠及全球更多患者。
关于复宏汉霖
复宏汉霖（2696.HK）是一家国际化的创新生物制药公司，致力于为全球患者提供可负担的高品质生物药，产品覆盖肿瘤、自身免疫疾病、眼科疾病等领域，已在中国上市5款产品，在国际上市1款产品，18项适应症获批，3个上市申请分别获中国药监局、美国FDA和欧盟EMA受理。自2010年成立以来，复宏汉霖已建成一体化生物制药平台，高效及创新的自主核心能力贯穿研发、生产及商业运营全产业链。公司已建立完善高效的全球创新中心，按照国际药品生产质量管理规范（GMP）标准进行生产和质量管控，不断夯实一体化综合生产平台，其中，上海徐汇基地已获得中国和欧盟GMP认证，松江基地（一）也已获得中国GMP认证。
复宏汉霖前瞻性布局了一个多元化、高质量的产品管线，涵盖20多种创新单克隆抗体，并全面推进基于自有抗PD-1单抗H药汉斯状®的肿瘤免疫联合疗法。继国内首个生物类似药汉利康®（利妥昔单抗）、中国首个自主研发的中欧双批单抗药物汉曲优®（曲妥珠单抗，欧洲商品名：Zercepac®，澳大利亚商品名：Tuzucip®和Trastucip®）、汉达远®（阿达木单抗）和汉贝泰®（贝伐珠单抗）相继获批上市，创新产品汉斯状®（斯鲁利单抗）已获批用于治疗微卫星高度不稳定（MSI-H）实体瘤、鳞状非小细胞肺癌和广泛期小细胞肺癌，成为全球首个获批一线治疗小细胞肺癌的抗PD-1单抗，其食管鳞状细胞癌适应症的上市注册申请也正在审评中。公司亦同步就16个产品在全球范围内开展30多项临床试验，对外授权全面覆盖欧美主流生物药市场和众多新兴市场。
HenliusWelcomedSABMember AlbertoMantovanitoitsShanghaiInnovationCentre
Recently,AlbertoMantovani,amemberofHenlius’ScientificAdvisoryBoard(SAB),ScientificDirectorandEmeritusProfessoratHumanitasClinicalandResearchCenterinItaly,visitedHenlius’ShanghaiInnovationCentreandsharedinsightsandengagedindiscussionsregardingcutting-edgetechnologiesandglobalinnovationtrends.
Prof.Mantovaniisarenownedexpertinthefieldsofimmunologyandinflammation,possessingextensiveresearchexperience.Hehasmadesignificantcontributionstothefieldofinflammationanditsrelationshipwithoncology.Duringtheseminar,Prof.Mantovanideliveredapresentationtitled"InnateImmunityandInflammation,fromCancertoCOVID-19".DrawingfromhisresearchexpertiseandHenlius’discoveryresearch,hesharedinsightsonthecriticalrolesofimmuneandinflammatorymediatorsincludingmacrophages,familiesofinterleukin-1(IL-1)andreceptors(IL-1R)indiseaseprogression,therapyandprevention.Moreover,heexplainedtheintricateinterconnectionsbetweeninnateimmunity,inflammation,andthepathogenesisofvariousdiseases,suchascancerandCOVID-19,aswellasstrategiesforsystemictreatment.Hethenheldanin-depthdiscussionwiththeattendingscientistsatHenlius.
Dr.YongqiangShan,generalmanagerofShanghaiInnovationCentre,expressedgratitudetoProf.Mantovaniforsharinghisprofessionalknowledgeandinsightsduringtheseminar. ThecollaborationwiththemembersoftheSAB,includingProf.Mantovani,willhelpthecompanyinitsresearch-and-developmentdirectionandwillleadtomoretechnologicalinnovations.Henlius’researchersbenefittedfromProf.Mantovani'svisitbyengagingdirectlyinadirectdialoguewithoneoftheworld'stopminds,whichenabledthemtostaycurrentwithrecentdevelopmentsinthefield.ThecollisionofknowledgeandideaswillgreatlyfacilitateHenlius'furtherdevelopmentofnoveltherapiesandtherealizationofitsvisiontoaddressunmetclinicalneeds.
Movingforward,Henliuswillcontinuetofosterdialoguewithmoregloballeadingscientists,promotethetranslationofscientificachievements,acceleratethedevelopmentofinnovativetherapies,andultimatelybenefitmorepatientsworldwide.
AboutHenlius
Henlius(2696.HK)isaglobalbiopharmaceuticalcompanywiththevisiontoofferhigh-quality,affordable,andinnovativebiologicmedicinesforpatientsworldwidewithafocusononcology,autoimmunediseases,andophthalmicdiseases.Uptodate,5productshavebeenlaunchedinChina,1hasbeenapprovedformarketinginoverseasmarkets,18indicationsareapprovedworldwide,and3marketingapplicationshavebeenacceptedforreviewinChina,theU.S.,andtheEU,respectively.Sinceitsinceptionin2010,Henliushasbuiltanintegratedbiopharmaceuticalplatformwithcorecapabilitiesofhigh-efficiencyandinnovationembeddedthroughoutthewholeproductlifecycleincludingR&D,manufacturingandcommercialization.IthasestablishedglobalinnovationcentersandShanghai-basedmanufacturingfacilitiesinlinewithglobalGoodManufacturingPractice(GMP),includingXuhuiPlantcertificatedbyChinaandtheEUGMPandSongjiangFirstPlantcertificatedbyChinaGMP.
Henliushaspro-activelybuiltadiversifiedandhigh-qualityproductpipelinecoveringover20innovativemonoclonalantibodies(mAbs)andhascontinuedtoexploreimmuno-oncologycombinationtherapieswithproprietaryHANSIZHUANG(anti-PD-1mAb)asbackbone.ApartfromthelaunchedproductsHANLIKANG(rituximab),thefirstChina-developedbiosimilar,HANQUYOU(trastuzumabforinjection,tradenameinEurope:Zercepac®;tradenamesinAustralia:Tuzucip® andTrastucip®,thefirstChina-developedmAbbiosimilarapprovedbothinChinaandEurope,HANDAYUAN(adalimumab)andHANBEITAI(bevacizumab),theinnovativeproductHANSIZHUANGhasbeenapprovedbytheNMPAforthetreatmentofMSI-Hsolidtumors,squamousnon-smallcelllungcancer(sqNSCLC)andextensive-stagesmallcelllungcancer(ES-SCLC),makingittheworld’sfirstanti-PD-1mAbforthefirst-linetreatmentofSCLC.ItsNDAforthetreatmentofesophagealsquamouscellcarcinoma(ESCC)isunderreview.What'smore,Henliushasconductedover30clinicalstudiesfor16products,expandingitspresenceinmajormarketsaswellasemergingmarkets.